Proactive Investors - Run By Investors For Investors

CannPal Animal Therapeutics managing director buys more shares on-market

A number of board members have purchased shares in the company in 2019 to date.
three empty board seats
The shares were purchased at an average price of 15.5 cents each

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills has purchased 65,000 shares in the company via on-market trades.

The $10,075 parcel of shares increases Mills’ total holding in the company to over 7.57 million shares.

READ: CannPal Animal Therapeutics files new patent application as industry-leading research is recognised

The share purchase from Mills follows purchases from Max Johnston in March, chairman Geoff Starr in February, and Robert Clifford in January this year.

CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals such as dogs and cats.

CPAT-01 is the company’s lead drug candidate under development targeting pain and inflammation control in dogs.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CP1 profile View Profile

CannPal Animal Therapeutics Ltd Timeline

Related Articles

Sydney Harbour Bridge
January 23 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
medicinal cannabis concept
January 31 2019
Zelda has released its December quarterly report confirming multiple trials are on track.
cannabis extract
January 17 2019
The Kelowna, BC-based cannabis company specializes in the research, development, production, and testing of high-quality cannabis extracts and oils

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use